The let-7 microRNA (miRNA) family has been implicated in the regulation of diverse cellular processes and disease pathogenesis. In cancer, loss-of-function of let-7 miRNAs has been linked to tumorigenesis via increased expression of target oncogenes. Excessive proliferation rate of tumor cells is often associated with deregulation of mitotic proteins.
Introduction
MicroRNAs (miRNAs) are small 18e25 nucleotide-long noncoding RNA molecules that regulate a wide range of physiological and pathological processes (He and Hannon, 2004) . A miRNA generally binds to the 3 0 UTR of the target messenger RNA (mRNA) and either represses its translation or directs the mRNA for degradation (He and Hannon, 2004) . Some miRNAs have also been reported to bind the coding region or 5 0 UTR of the target mRNA (Forman et al., 2008; Lytle et al., 2007) . In addition to regulation of animal development and tissue differentiation, several miRNAs are implicated in cell transforming processes that can contribute to cancer initiation, progression and metastasis (Farazi et al., 2011) . MiRNAs that promote tumorigenesis are termed onco-miRNAs whereas tumor suppressor miRNAs are associated with anti-cancer pathways. Even though cancer is characterized by excessive rate of cell division very little is known about the miRNAmediated regulation of mitosis. However, recently a few miRNAs have been reported to influence cell division through the regulation of mitosis-associated genes (Bhattacharjya et al., 2013; He et al., 2013) and many more miRNAs are anticipated to control mitosis. In mitosis, faithful chromosome segregation is essential for the maintenance of genomic balance and normal growth. Therefore, mitosis is under the control of a signalling network termed the spindle assembly checkpoint (SAC) (Musacchio, 2011) . In the presence of unstable kinetochore-microtubule attachments or erroneous spindle structure, the SAC halts mitosis progression allowing more time for correction of mistakes that could lead to increased genomic instability. In case of severe mitotic defects, cells typically arrest to M phase for several hours before they either exit mitosis normally upon successful error correction, or alternatively die or slip out of mitosis with chromosomal errors. The cell fate depends on the balance between the SAC, cell cycle, and cell death signalling (Gascoigne and Taylor, 2008) . Loss or gain of chromosomes, which is the cause of aneuploidy, and induction of polyploidy by cytokinesis failure are associated with numerical chromosomal instability (CIN), one of the hallmarks of cancer (Li et al., 2009; Musacchio, 2011) . Earlier studies have shown that altered expression of certain mitotic proteins, for example Cenp-E and Mad2, contributes to induction of aneuploidy (Sotillo et al., 2007; Weaver et al., 2007) . Interestingly, aneuploidy has a dual role in tumorigenesis; tolerable low levels of aneuploidy can provide cancer cells with a growth advantage whereas high levels of aneuploidy usually induce cell death (Weaver et al., 2007) .
Also, altered Aurora B expression and kinase activity can lead to perturbation of mitosis causing aneuploidy and polyploidy (Hauf et al., 2003; Ota et al., 2002; Terada et al., 1998) . In vivo, Aurora B is often highly expressed in cancer, which is linked to poor patient prognosis (Carter et al., 2006) . The kinase is an essential component of the SAC and the catalytic subunit of the chromosomal passenger complex (CPC) composed of three other main subunits, INCENP, Survivin and Borealin (Ditchfield et al., 2003; Gassmann et al., 2004; Hauf et al., 2003) . At the centromeres, Aurora B destabilizes erroneous kinetochore-microtubule attachments by phosphorylating outer kinetochore protein Hec1 that mediates the connections between microtubules and chromosomes (DeLuca et al., 2006 (DeLuca et al., , 2011 . Besides the SAC signalling, Aurora B contributes to other mitotic events including chromatin organization and cytokinesis through its action on substrates such as centralspindlin (Guse et al., 2005) , condensin I (Lipp et al., 2007) and histone H3 (Hirota et al., 2005) .
The let-7 miRNA family is widely studied for its regulatory effects on cell differentiation, proliferation, and developmental timing (Johnson et al., 2007; Roush and Slack, 2008) . Altered expression of the family members can however lead to reprogramming of these normal processes and stimulate malignant cell proliferation and cancer metastasis (Johnson et al., 2007; Yu et al., 2007) . In the majority of human cancers, let-7 is considered to function as a tumor suppressor miRNA inhibiting cancer cell proliferation and tumor growth (He et al., 2010; Johnson et al., 2007; Yu et al., 2007) . However, in certain cancers, like in certain lymphomas (Lawrie et al., 2009) , let-7 is linked to enhanced cancer progression. Here, we have investigated the impact of excess let-7b on mitotic signalling and genomic stability. We report that let-7b directly targets the mRNA of Aurora B kinase and consequently reduces Aurora B protein levels and kinase activity leading to chromosomal and spindle errors. In cells, excess let-7b induced polyploidy, aneuploidy, and premature exit from mitosis, which are phenotypes previously associated with Aurora B loss-of-function (Hauf et al., 2003; Marxer et al., 2014) . Furthermore, let-7b overexpression had an additive effect on polyploidy induction together with chemical Aurora B inhibition in HeLa cells. In breast cancer patient samples, we found that let-7b expression negatively correlates with tumor grade and Aurora B expression. Also, let-7b expression was lower in estrogen receptor (ER) negative, human epidermal growth factor receptor 2 (HER2) positive and TP53 mutated cancers. Together, our results indicate that altered let-7b expression can modulate Aurora B expression and thereby have an impact on mitotic fidelity and tumorigenesis.
2.
Materials and methods 
Chemicals
Nocodazole (M1404; SigmaeAldrich, St. Louis, MO, USA) was used at 150 nM, taxol (Paclitaxel; T7191; SigmaeAldrich) at 100 nM, ZM447439 (2458; Tocris Bioscience) at 20 mM, MG132 (C2211; SigmaeAldrich) at 20 mM, barasertib (AZD1152-HQPA; S1147; Selleckchem) at 3.125e50 nM, and thymidine (T9250; SigmaeAldrich) at 2 mM concentration.
2.3.
High-throughput screen 20 nM Human Pre-miR miRNA Precursor library v2 (Ambion; 319 molecules) or 20 nM miRIDIAN microRNA mimic library v10.1 (Dharmacon; 810 molecules) were screened for antimitotic miRNAs. Hamilton Microlab Star robotics (Hamilton) was used to print pre-miRNAs to 384-well plates. Transfection reagent siLentFect (Bio-Rad) and OptiMEM were added to plates using Multidrop Combi (Thermo Fisher Scientific). After 1 h incubation at room temperature (RT), HeLa H2B-GFP cells were added to plates and incubated for 60 h after which 150 nM nocodazole or 100 nM taxol was introduced for 12 h. For end-point analysis, cells were imaged with Zeiss inverted 200 M microscope (Zeiss GmbH) and Metamorph software version 6.2r6 (Molecular Devices) or ScanR imaging software (Olympus Corporation).
MicroRNAs, target site blockers and transfections
The pre-miRNAs (Pre-miRä miRNA Precursors hsa-let-7b-5p and negative controls #1 and #2) used in cell based target validation were purchased from Ambion. 
Immunoblotting
For Western blotting, cells were centrifuged and washed with cold PBS prior to freezing the pellets in liquid nitrogen. Cells were thawed and lysed in 20 mM TriseHCl (pH 7.7), 100 mM KCl, 50 mM sucrose, 1 mM MgCl 2 , 0.1 mM CaCl 2 , 0.5% Triton X-100 (APC-buffer) containing protease inhibitor cocktail (04693132001; Roche) and phosphatase inhibitor PhosSTOP (4906837001; Roche) for 7e10 min on ice followed by centrifugation. Samples were run on 4e20% gradient gels (Bio-Rad 
Fluorescence in situ hybridization (FISH)
HCT-116 cells were trypsinized and incubated in 0.075 M KCl hypotonic solution for 15 min at 37 C. Then the cells were fixed using methanol:acetic acid (3:1) for 1 h at 4 C. The cells were pelleted and resuspended in fresh fixative, and dropped on a clean glass slide (Superfrost from Thermo Fisher Scientific). The glass slide was incubated for minimum 10 min at RT. Vysis LSI ETV6(TEL)/RUNX1(AML1) ES Dual color probe and Vysis LSI 13(13q14) SpectrunGreen probe (Abbott Inc.) were used. The slides were prepared according to the manufacturer's instructions. The Image acquisition and analysis was done using ScanR Imaging system (Olympus Corporation).
Clinical data analyses
Primary breast carcinoma samples from 101 patients part of the MicMa cohort (Naume et al., 2001) were profiled for miRNA expression using the 8 Â 15 k "Human miRNA Microarray Kit (V2)" with design id 019118 from Agilent (Agilent Technologies). In brief, 100 ng total RNA was dephosphorylated, labeled and hybridized for 20 h, following the manufacturer's protocol. Scanning was performed on Agilent Scanner G2565A, signals were extracted using Feature Extraction v9.5 and the subsequent data processing was performed using the GeneSpring software v12.0 (Agilent Technologies). MiRNA signal intensities were log 2 -transformed and for each sample normalized to the 90th percentile. MiRNAs that were detected in less than 10% of the samples were excluded. The miRNA expression data was published (Enerly et al., 2011) and has been submitted to the Gene Expression Omnibus (GEO) with accession number GSE19536. The mRNA expression data were measured using Agilent 4 Â 44 K one-color oligonucleotide arrays (Agilent Technologies), published earlier (Enerly et al., 2011) and submitted to GEO with accession number GSE19783. The patient clinical information is described earlier (Naume et al., 2007) and the molecular subtype classification based on mRNA expression was derived using the PAM50 gene list (Parker et al., 2009 ).
Statistical analysis
The Student's T-test was used for performing statistical analysis if not stated otherwise. For analysis of FISH results, Chi-square test was used. Values are presented as mean AE standard deviation (SD). For analyzing miRNA expression in clinical data groups, The Student's t-test was applied to evaluate differences in miRNA expression among two groups, and the ANOVA test was applied to evaluate differences between three or more groups. The log-rank test was used to determine differences between survival curves. Statistical significance was denoted as p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***).
Results

Excess let-7b induces mitotic defects and affects cell cycle progression
Let-7b-5p (Supplementary Figure A.1A) , henceforth called let7b, was identified as a potential mitosis and cell cycle regulating miRNA in a high-throughput screen (HTS) for antimitotic miRNAs performed earlier. In total, the HTS yielded seven strong hit miRNAs that are all under further investigations. As the third strongest hit miRNA, let-7b induced pleiotropic mitotic phenotype including formation of multilobed nuclei after override of chemically induced mitotic block as well as induction of polyploidy in drug-free culture conditions (data not shown). The transient transfection of pre-miRNA let7b into HeLa cells induced a significant elevation in the let-7b expression compared to controls (Supplementary Figure A.1B) . To confirm the HTS results, we used time-lapse microscopy to determine cell fates in let-7b or control miRNA overexpressing HeLa cells treated with the microtubule drug nocodazole ( Figure 1A and Supplementary Movies S1-2). The analysis of the films indicated that HeLa cells with excess let-7b exhibited significantly increased frequency of forced mitotic exit (47.5%) from nocodazole block in comparison to control (18.8%) (Figure 1AeB ). In drug-free culture conditions, overexpression of let-7b led to mitotic delay in comparison to controls. The average duration of mitosis in the let-7b transfected HeLa cell population was 3.7 AE 4.6 h compared to 1.3 AE 1.3 h observed in the control population ( Figure 1B) . Moreover, the analysis of cell fates indicated that excess let7b lowered cell viability compared to controls. In drug-free culture conditions, 31.3% of the let-7b overexpressing cells underwent cell death after prolonged mitosis of 9.1 AE 4.9 h whereas 5.0% of control cells died in mitosis with mitotic duration of 5.3 AE 4.8 h ( Figure 1B) . Supplementary video related to this article can be found at http://dx.doi.org/10.1016/j.molonc.2015.01.005.
To confirm the M phase effects and identify any premitotic cell cycle delays, HeLa cells transfected with let-7b or control miRNA were synchronized with double thymidine block and time-lapse filmed for 18 h after thymidine washout ( Figure 1C ). In the drug-free culture conditions, no significant difference was observed in timing of M phase entry between let-7b and control miRNA overexpressing cells. However, the mitotic index (MI) was slightly higher in the let-7b transfected cell population (6.7 AE 2.7% at 18 h after thymidine washout) compared to controls (2.0 AE 0.6% at 18 h after thymidine washout). In the synchronized and microtubule drug treated cell populations, the MI was higher over time after thymidine washout in the control miRNA transfected cells (in the presence of nocodazole and taxol 69.6 AE 2.6% and 77.4 AE 8.8%, respectively, at 18 h after thymidine washout) in comparison to the let-7b overexpressing cells (in the presence of nocodazole and taxol 58.9 AE 3.5% and 62.7 AE 5.9%, respectively, at 18 h after thymidine washout). To further characterize the cell cycle effects, let-7b and control miRNA overexpressing HeLa cells were subjected to flow cytometric analysis. In the control cell population, 13.3 AE 2.0% of the cells were at G2/M (4n) phase whereas in the let-7b overexpressing cell population significantly more cells (25.7 AE 4.0%) exhibited 4n DNA content ( Figure 1D ). In flow cytometric analysis, 4n DNA content can refer to G2 and M phase cells but also to cells that have exited from mitosis without cytokinesis. In addition, the frequency of polyploid 8n cells was significantly increased in the let-7b transfected cell population (2.5 AE 0.1%) compared to control (1.6 AE 0.3%). We conclude that the excess of let-7b causes disturbances in mitosis that are associated with increased frequency of forced exit from microtubule drug imposed M phase block, elevated induction of polyploidy and lowered cell viability.
3.2.
Let-7b diminishes Aurora B mRNA and protein levels by targeting the 3 0 UTR of the kinase
The mitosis perturbing phenotype of let-7b overexpression prompted us to search for mitotic target genes of the miRNA.
According to TargetScan target prediction software (TargetScanHuman 6.2; Garcia et al., 2011) Aurora B is one of the possible targets of let-7b. Earlier studies have associated Aurora B inhibition with forced mitotic exit and override of microtubule drug induced M phase arrest (Kallio et al., 2002) , which led us to investigate the impact of let-7b on the kinase expression. Both the mRNA and protein levels of Aurora B were found to be significantly (p < 0.05) decreased, by 42.3% and 34.6% respectively, in the let-7b overexpressing HeLa cells compared to controls (Figure 2AeB ). Moreover, analysis of immunostained cells indicated that excess of let-7b caused a significant (p < 0.001) reduction in the amount of centromeric (p < 0.01) compared to controls determined with Aurora B 3 0 UTR plasmid and the full length Aurora B plasmid, respectively ( Figure 3A) . To verify the binding, the predicted binding site of let-7b on Aurora B was mutated with site-directed mutagenesis. When either of the mutant plasmids were transfected into let-7b overexpressing cells, the luciferase activity on Aurora B (AURKB) is shown, and the binding sequence of let-7b is underlined. Data are from four separate experiments (mean ± SD). B, Sitedirected mutagenesis of Aurora B 3 0 UTR prevents let-7b binding determined by luciferase reporter assays. Indicated bases (red) were mutated on Aurora B. Data are from five separate experiments (mean ± SD). C, Let-7b target site blocker (TSB) rescues Aurora B protein levels in cells with excess let-7b. HeLa cells transfected with 40 nM miR-control, let-7b, control TSB or let-7b TSB in different combinations as indicated were extracted for Western blotting to detect Aurora B protein levels 48 h post-transfection. GAPDH was used as a loading reference. TSB sequence and a part of Aurora B mRNA 3 0 UTR are shown. The region of TSB corresponding let-7b binding sequence is underlined. Data are from three separate experiments (mean ± SD). The asterisks denote statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001). 0 1 5 ) 1 0 5 6 e1 0 7 0 remained at the basal control level indicating that let-7b binds to the predicted site in Aurora B mRNA ( Figure 3B ). Next, we attempted to functionally rescue the suppression of Aurora B protein induced by let-7b. TSB was designed to bind to Aurora B mRNA and compete for binding with let-7b. In cells transfected with both let-7b and TSB, Aurora B protein levels were restored back to the control level ( Figure 3C ). Our results suggest that let-7b directly binds to a specific site in the Aurora B 3 0 UTR causing reduction of Aurora B mRNA and protein levels as well as perturbation of mitotic events dependent on normal Aurora B kinase activity.
Excess of let-7b induces aneuploidy and multipolarity
Altered Aurora B expression and activity have been linked to genomic instability (Kallio et al., 2002; Ota et al., 2002) . To investigate the impact of let-7b on induction of aneuploidy, we measured numerical chromosome changes using a neardiploid colon cancer HCT-116 cell line. First, we determined Aurora B mRNA and protein levels in HCT-116 cells transfected with let-7b or control miRNA. The excess of let-7b was found to reduce the kinase levels in comparison to The graphs show quantification of copy numbers in a pool of 800e1 200 cells for both miR-control and let-7b transfected cell populations. Data are from 2 to 3 separate assays per a probe (mean ± SD). The asterisks denote statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001). controls ( Figure 4AeB) . Next, using fluorescence in situ hybridization (FISH) we determined possible copy number changes of the chromosomes 12, 13 and 21. Analysis revealed significant elevation in the frequency of monosomy, trisomy, and tetrasomy by excess of let-7b in comparison to controls ( Figure 4C ). For example, let-7b overexpression increased monosomy to 12.8 AE 1.3% and trisomy to 12.5 AE 2.0% compared to control's 6.4 AE 1.5% and 6.6 AE 1.9%, respectively, determined with a probe for chromosome 12.
In addition to the numerical chromosome changes, let-7b transfected HeLa cells manifested multipolar spindles, which is in line with earlier work reporting induction of polyploidy upon Aurora B inhibition (Kallio et al., 2002) . The structure of mitotic spindle was visualized in let-7b and control miRNA transfected HeLa cells using immunofluorescence with antibodies against a-tubulin and pericentrin. Let-7b transfected HeLa cell populations showed significant increase in the number of mitotic cells with more than two poles as 57.7 AE 12.7% of let-7b transfected cells were multipolar compared to 8.9 AE 5.0% of control population ( Figure 5 ). This resembled closely the impact of chemical inhibition of Aurora B as HeLa cells treated with a chemical Aurora B inhibitor ZM447439 in the presence of a proteasome inhibitor MG132 exhibited high rate of multipolarity (68.9 AE 8.6%) (Supplementary Figure A. 3). These results indicate that let7b induces multipolarity and aneuploidy, which are both phenotypes associated with Aurora B inhibition.
3.4.
Let-7b overexpression has an additive effect on induction of polyploidy in the presence of the Aurora B inhibitor barasertib Barasertib (AZD1152) is a specific Aurora B inhibitor in phase II clinical trials for treatment of acute myeloid leukemia (Kantarjian et al., 2013) . Since the drug induces mitotic slippage and polyploidy in cells (Marxer et al., 2014) , we investigated its possible synergistic or additive effects on the cellular phenotype observed in the let-7b overexpressing cells. HeLa cell populations overexpressing let-7b or control miRNA were subjected to treatments with different concentrations of barasertib. The range of concentrations (3.125e50 nM) was chosen based on an earlier study reporting that 12.5 nM barasertib increases the frequency of polyploid cells (Marxer et al., 2014) . After 24 h drug incubation, the DNA content of the cell populations was profiled using flow cytometry. The analysis showed that control miRNA transfected Hela cells exhibited increase in 4n and 8n populations when treated with 12.5 nM barasertib as expected (Figure 6 ). Interestingly, excess let-7b in combination with barasertib induced more polyploidy compared to barasertib with control miRNA. The difference in polyploidy between control miRNA and let-7b transfected cells was restored throughout the used concentration range but in cells treated with higher barasertib concentrations the differences became smaller. Together, our data suggest that let-7b has an additive effect on induction of polyploidy in combination with the Aurora B inhibitor barasertib.
3.5.
Low let-7b expression correlates with high tumor grade, positive HER2 status, negative ER status and mutated TP53 in breast cancer patients Earlier in vitro and xenograft studies have suggested tumor suppressor functions for the let-7 family (Esquela-Kerscher et al., 2008; Johnson et al., 2005; Kumar et al., 2008) . Moreover, in patients with lung and ovarian cancer, reduced expression of let-7 family members has been found to correlate with poor prognosis (Nam et al., 2008; Takamizawa et al., 2004) . Here, we retrospectively analyzed let-7b expression in a breast cancer patient cohort composed of 101 patients whose tumors were profiled for expression of 799 miRNAs (Enerly et al., 2011) .
Figure 5 e Let-7b overexpression induces multipolarity in HeLa cells. Cells were transfected with 40 nM let-7b or miR-control, fixed 48 h posttransfection and immunostained with antibodies against pericentrin (red) and a-tubulin (green). DNA was stained with DAPI (blue). Scale bar equals 10 mm. The graph shows quantification of mitotic cells with either bipolar or multipolar spindles in let-7b and miR-control transfected cell populations (n [ 75e105). Data are from three separate experiments (mean ± SD). The asterisks denote statistical significance (**p < 0.01).
We found that let-7b expression inversely correlated with increasing tumor grade (p < 0.001) and was significantly reduced in the HER2 and basal-like tumor subtypes compared to the normal-like and luminal A and B cancer subtypes (Figure 7AeB ). These previously established molecular subtypes of breast cancer are based on gene expression (Perou et al., 2000; Sorlie et al., 2001) and are associated with survival of which the basal-like subtype has the worst prognosis. Relapse-free survival records were available for 96 patients of the Micma cohort. When the patients were divided into high and low let-7b expression groups (above or below median expression), low let-7b expression was associated with poorer survival compared to high let-7b expression (p < 0.05; Figure 7C ). Furthermore, let-7b expression was significantly lower in HER2 positive tumors, ER negative tumors and TP53 mutated tumors compared to the opposite statuses (Figure 7DeF ). In accordance with our data showing that let7b targets Aurora B mRNA, let-7b expression was found to inversely correlate with Aurora B expression in different tumor grades (Pearson correlation À0.41, p < 0.001). For example, in the grade 3 tumors let-7b was markedly reduced while expression of Aurora B was notably elevated ( Figure 7G ). Next, we investigated The Cancer Genome Atlas Network database to see if our observations can be reproduced using another dataset (Cancer Genome Atlas Network, 2012) . The let-7b expression was available for 395 -7a, let-7b, let-7c, let-7e and let-7f all are downregulated in tumors of higher grade. Interestingly, this was a more evident trend for the -5p forms of miRNAs compared to the -3p forms originating from the same hairpin loops of these individual miRNAs. Importantly, of all the let-7 family miRNAs we analyzed, let-7b-5p was the most significantly downregulated family member in ER negative, HER2 positive and TP53 mutated tumors, and showed the strongest negative correlation with increasing tumor grade (Supplementary Table A.1). In conclusion, our data indicate loss of let-7b expression in more aggressive forms of breast cancer, which correlates with increased expression of the Aurora B kinase.
Discussion
Let-7b is a member of the let-7 family of miRNAs that are implicated in oncogenesis as tumor suppressors (He et al., 2010; Johnson et al., 2007) . Let-7 miRNAs control the expression of a number of oncogenes, such as RAS and MYC, and thereby reduce cancer cell proliferation and tumor development (Johnson et al., 2007 (Johnson et al., , 2005 ; Kumar et al., 2008; Sampson et al., 2007) . Also, it has been suggested based on an mRNA Figure 6 e Excess let-7b has an additive effect on the induction of polyploidy in combination with the Aurora B inhibitor barasertib. HeLa cells transfected with 40 nM miR-control or let-7b were subjected to flow cytometric cell cycle analysis 48 h post-transfection. Barasertib was added to cells at indicated concentrations 24 h before cell harvesting. Representative flow cytometric profiles are shown. The histogram depicts the data from three separate experiments (mean ± SD). The asterisks denote statistical significance (*p < 0.05, **p < 0.01).
array study that let-7b indirectly or directly affects the Aurora B kinase levels (Johnson et al., 2007) . The effects of let-7 miRNAs on mitosis have, however, remained largely unknown. Here, we show that let-7b binds to the 3 0 UTR of the Aurora B kinase, a mitotic kinase essential for the proper function of the SAC and normal chromosome segregation. Let-7b overexpression decreased the mRNA and protein levels of Aurora B in cells, which was associated with mitotic defects and induction of aneuploidy and polyploidy. The luciferase reporter assays and TSB rescue experiments confirmed that let-7b directly targeted Aurora B mRNA for decay. High Aurora B expression and low let-7b expression have both been separately reported to correlate with a poor patient prognosis (Kurai et al., 2005; Nam et al., 2008) . Our results extend the earlier findings showing significant correlation between low let-7b expression and high Aurora B expression in high grade breast tumors. Together with the observed anti-mitotic effects of excess let-7b these results provide a mechanistic explanation of how altered let-7b expression may drive tumorigenesis via perturbation of Aurora B dependent cellular processes. Since each miRNA can have several target genes, it is possible that other cell cycle regulators, in addition to Aurora B, become abnormally suppressed by excess let-7b and thereby contribute to the observed cellular phenotype. However, most, if not all, mitotic anomalies observed in let-7b overexpressing cells can be associated with Aurora B malfunction. Induction of polyploidy and multipolarity are prominent consequences of Aurora B inhibition as the kinase affects central spindle localization and the completion of cytokinesis by e.g. phosphorylating the centralspindlin complex (Guse et al., 2005) . Also, syntelic chromosome attachments and lagging chromosomes leading to aneuploidy have been reported to be consequences of Aurora B inhibition (Hauf et al., 2003; Honda et al., 2003; Tanaka et al., 2002) . Furthermore, in non-perturbed growth conditions the duration of mitosis was prolonged in cells with excess let-7b. This is possibly caused by cells' initial response to improper kinetochore-microtubule interactions that are not efficiently corrected due to reduced Aurora B activity. This notion is further supported by our observations that low concentrations of the Aurora B inhibitor barasertib induced transient mitotic arrest (data not shown). Moreover, let-7b overexpression caused exit from microtubule drug induced M phase arrest, which indicates impaired Aurora B dependent SAC signalling. This closely resembles the outcome of chemical Aurora B inhibition, which causes cancer cells treated with microtubule poisons to undergo forced mitotic exit (Ditchfield et al., 2003; Hauf et al., 2003) .
The let-7 family members share the same seed sequence, the nucleotides 2-8 at their 5 0 ends (Farazi et al., 2011) , and often have similar functional consequences (Roush and Slack, 2008) . This may explain why many family members, such as let-7a, let-7c, let-7e and let-7f, showed a similar trend of expression as let-7b in different clinical groups of breast cancer. Also, let-7c, let-7e and let-7f came up as hit miRNAs in our original HTS (data not shown). It is, however, noteworthy that let-7b exhibited the most significant expression decrease associated with increasing tumor grade compared to other family members. Let-7a had very similar expression profile as let-7b, which could result from the nearby genomic localization of let-7a-3 and let-7b on chromosome 22 enabling common promoter regulation e.g. via NF-kB (Wang et al., 2012) . Interestingly, in endometrial carcinoma also let-7a has been reported to target Aurora B kinase (Liu et al., 2013) but the impact of this miRNA on mitotic phenotype has not been characterized. From a clinical perspective our findings can have diagnostic and therapeutic value. First, our findings reveal the association between low let-7b expression and poorer survival compared to patients with high let-7b expression. Also, the observation that let-7b is lower expressed in HER2 positive, TP53 mutated and ER negative breast cancers may have prognostic significance as these forms of breast cancer are generally associated with reduced patient survival. Moreover, restoration of let-7b expression in such tumors could potentially have beneficial effects on prognosis. Secondly, let-7b overexpression was found to cause forced exit from microtubule drug induced M phase arrest and may antagonize microtubule drug effects via premature inactivation of the SAC. Since taxanes and epothilones are the first line chemotherapeutics in the treatment of breast cancer (Dumontet and Jordan, 2010) , analysis of tumors' let-7b expression may assist in prediction of drug efficacy in the future. Lastly, excess let-7b had an additive effect on the induction of polyploidy in the presence of low concentrations of barasertib. This observation may allow the use of let-7b expression profiling in stratification of patients for future Aurora B therapies. However, we cannot exclude the possibility that the effects of barasertib and let-7b overexpression are independent.
In summary, based on our in silico findings and experiments in cells, we hypothesize that let-7b functions as one of the molecular switches that control Aurora B expression post-transcriptionally. Altered expression of let-7b could contribute both to cancer initiation and progression by regulating Aurora B dependent mitotic processes. For example, in the later stages of tumorigenesis low let-7b expression may not be able to suppress Aurora B and target oncogenes, which can provide cells with a growth and survival advantage. The potency of let-7b as a biomarker for tumor grade and drug efficacy should be addressed in more detail in the future.
